Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-interleukin-8 monoclonal antibody

Drug Profile

Anti-interleukin-8 monoclonal antibody

Alternative Names: ABX-IL8; Anti-IL-8 antibody

Latest Information Update: 10 Sep 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XenoTech LLC
  • Developer Abgenix; XenoTech
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Inflammation; Inflammatory bowel diseases; Malignant melanoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 02 Dec 2004 A study has been added to the adverse events and Respiratory Tract Disorders therapeutic trials sections
  • 22 Mar 2004 ABX-IL8 is available for licensing in the indication of chronic obstructive pulmonary disease (http://www.abgenix.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top